Literature DB >> 19657464

LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

William C Cromwell1, James D Otvos, Michelle J Keyes, Michael J Pencina, Lisa Sullivan, Ramachandran S Vasan, Peter W F Wilson, Ralph B D'Agostino.   

Abstract

BACKGROUND: The cholesterol content of LDL particles is variable, causing frequent discrepancies between concentrations of LDL cholesterol and LDL particle number. In managing patients at risk for cardiovascular disease (CVD) to LDL target levels, it is unclear whether LDL cholesterol provides the optimum measure of residual risk and adequacy of LDL lowering treatment.
OBJECTIVE: To compare the ability of alternative measures of LDL to provide CVD risk discrimination at relatively low levels consistent with current therapeutic targets.
METHODS: Concentrations of LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C) were measured chemically and LDL particle number (LDL-P) and VLDL particle number (VLDL-P) were measured by nuclear magnetic resonance (NMR) in 3066 middle-aged white participants (53% women) without CVD in the Framingham Offspring cohort. The main outcome measure was incidence of first CVD event.
RESULTS: At baseline, the cholesterol content per LDL particle was negatively associated with triglycerides and positively associated with LDL-C. On follow-up (median 14.8 yrs), 265 men and 266 women experienced a CVD event. In multivariable models adjusting for non-lipid CVD risk factors, LDL-P was related more strongly to future CVD in both sexes than LDL-C or non-HDL-C. Subjects with a low level of LDL-P (<25(th) percentile) had a lower CVD event rate (59 events per 1000 person-years) than those with an equivalently low level of LDL-C or non-HDL-C (81 and 74 events per 1000 person-years, respectively).
CONCLUSIONS: In a large community-based sample, LDL-P was a more sensitive indicator of low CVD risk than either LDL-C or non-HDL-C, suggesting a potential clinical role for LDL-P as a goal of LDL management.

Entities:  

Year:  2007        PMID: 19657464      PMCID: PMC2720529          DOI: 10.1016/j.jacl.2007.10.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  38 in total

Review 1.  Low-density lipoprotein particle number and risk for cardiovascular disease.

Authors:  William C Cromwell; James D Otvos
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

Review 2.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Authors:  Elias J Jeyarajah; William C Cromwell; James D Otvos
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

Review 3.  Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.

Authors:  Rodney A Hayward; Timothy P Hofer; Sandeep Vijan
Journal:  Ann Intern Med       Date:  2006-10-03       Impact factor: 25.391

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B.

Authors:  J R McNamara; D M Small; Z Li; E J Schaefer
Journal:  J Lipid Res       Date:  1996-09       Impact factor: 5.922

Review 6.  Metabolic origins and clinical significance of LDL heterogeneity.

Authors:  Kaspar K Berneis; Ronald M Krauss
Journal:  J Lipid Res       Date:  2002-09       Impact factor: 5.922

7.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

8.  Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial.

Authors:  Gavin J Blake; Michelle A Albert; Nader Rifai; Paul M Ridker
Journal:  Eur Heart J       Date:  2003-10       Impact factor: 29.983

9.  Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.

Authors:  Allan D Sniderman; Annie C St-Pierre; Bernard Cantin; Gilles R Dagenais; Jean-Pierre Després; Benoît Lamarche
Journal:  Am J Cardiol       Date:  2003-05-15       Impact factor: 2.778

10.  The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.

Authors:  S S Soedamah-Muthu; H M Colhoun; M J Thomason; D J Betteridge; P N Durrington; G A Hitman; J H Fuller; K Julier; M I Mackness; H A W Neil
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

View more
  113 in total

1.  The association between N-terminal pro B-type natriuretic peptide and lipoprotein particle concentration plateaus at higher N-terminal pro B-type natriuretic peptide values: Multi-Ethnic Study on Atherosclerosis.

Authors:  Otto A Sanchez; Daniel A Duprez; Lori B Daniels; Alan S Maisel; James D Otvos; Carmen A Peralta; João A Lima; Hossein Bahrami; David R Jacobs
Journal:  Metabolism       Date:  2015-04-15       Impact factor: 8.694

2.  The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: the Sea Islands Genetic African American Registry (Project SuGAR).

Authors:  Jasmin Divers; Michèle M Sale; Lingyi Lu; Wei-Min Chen; Kerry H Lok; Ida J Spruill; Jyotika K Fernandes; Carl D Langefeld; W Timothy Garvey
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

Review 3.  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.

Authors:  William C Cromwell; Thomas A Barringer
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

4.  The search beyond statins.

Authors:  Melinda Wenner Moyer
Journal:  Nat Med       Date:  2010-02       Impact factor: 53.440

5.  [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease].

Authors:  Si Chen; Jin-Zhen Zhao; Jing Hu; Zhi-Gang Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

6.  Reduction in dietary trans fat intake is associated with decreased LDL particle number in a primary prevention population.

Authors:  M Garshick; H Mochari-Greenberger; L Mosca
Journal:  Nutr Metab Cardiovasc Dis       Date:  2013-10-05       Impact factor: 4.222

7.  Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy.

Authors:  Monique A Ford; Joseph P McConnell; Shahar Lavi; Charanjit S Rihal; Abhiram Prasad; Gurpreet S Sandhu; Stacy J Hartman; Lilach O Lerman; Amir Lerman
Journal:  Atherosclerosis       Date:  2009-05-06       Impact factor: 5.162

Review 8.  Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.

Authors:  Kiran Musunuru
Journal:  Lipids       Date:  2010-06-04       Impact factor: 1.880

9.  Superiority of lipoprotein particle number to detect associations with arterial thickness and stiffness in obese youth with and without prediabetes.

Authors:  Amy S Shah; W Sean Davidson; Zhiqian Gao; Lawrence M Dolan; Thomas R Kimball; Elaine M Urbina
Journal:  J Clin Lipidol       Date:  2016-02-16       Impact factor: 4.766

10.  Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.

Authors:  Robert S Rosenson; James D Otvos; Judith Hsia
Journal:  Diabetes Care       Date:  2009-03-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.